Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
The DOI matches its Crossref record; 281 of the 281 references it cites were found in a registry or an index.
Abstract
Epigenetic aberrations, which are recognized as key drivers of several human diseases, are often caused by genetic defects that result in functional deregulation of epigenetic proteins, their altered expression and/or their atypical recruitment to certain gene promoters. Importantly, epigenetic changes are reversible, and epigenetic enzymes and regulatory proteins can be targeted using small molecules. This Review discusses the role of altered expression and/or function of one class of epigenetic regulators--histone deacetylases (HDACs)--and their role in cancer, neurological diseases and immune disorders. We highlight the development of small-molecule HDAC inhibitors and their use in the laboratory, in preclinical models and in the clinic.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is increasing evidence that KDAC inhibitors work best in combination with other therapies [28–30]”
From Acetylation: a new target for protein degradation in cancer (2025) · cites this paper as [29]
In the citing paper
“Growing evidence supports that epigenetic dysregulation through histone deacetylases (HDACs) plays a critical role in synaptic dysfunction and memory loss in Alzheimer’s disease”
From CI-994 is a dual modulator of class I HDACs and Wnt/β-catenin signaling for the treatment of Alzheimer's disease (2026) · cites this paper as [4]
In the citing paper
“HDAC inhibitors can enhance histone acetylation and ameliorate cognitive impairments in various AD models, and HDAC inhibition has been recognized as an attractive therapeutic strategy for AD [4, 5, 7].”
From CI-994 is a dual modulator of class I HDACs and Wnt/β-catenin signaling for the treatment of Alzheimer's disease (2026) · cites this paper as [4]
In the citing paper
“HDAC inhibitors can enhance histone acetylation and ameliorate cognitive impairments in various AD models, and HDAC inhibition has been recognized as an attractive therapeutic strategy for AD [4, 5, 7].”
From CI-994 is a dual modulator of class I HDACs and Wnt/β-catenin signaling for the treatment of Alzheimer's disease (2026) · cites this paper as [4]
In the citing paper
“HDACs are epigenetic modulators that deacetylate lysine residues in histone and nonhistone substrates and their inhibition has attracted much interest for the treatment of neurodegenerative disorders, as several isoforms seem to be implicated in AD memory-related dysfunction: HDAC2 is a nuclear isoform that reduce transcription of CREB-regulated genes involved in learning and memory, HDAC6 targets”
From From combinations to multitarget-directed ligands: A continuum in Alzheimer’s disease polypharmacology (2021) · cites this paper as [118]
Citations
Cites
4 retracted
Items 201–281 of 281
Bridle, B. W., Chen, L., Lemay, C. G., Diallo, J., Pol, J. G., Nguyen, A., Capretta, A. A., He, R., Bramson, J. L., Bell, J. C., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2012.265 · Cited by 113
Joosten, L. A. B., Leoni, F., Meghji, S., & Mascagni, P. (2011) · Molecular Medicine · doi:10.2119/molmed.2011.00058 · Cited by 113
Hug, B. A., & Lazar, M. A. (2004) · Oncogene · doi:10.1038/sj.onc.1207674 · Cited by 112
Navarro, M. N., Goebel, J., Feijoo-Carnero, C., Morrice, N., & Cantrell, D. A. (2011) · Nature Immunology · doi:10.1038/ni.2008 · Cited by 107
Shakespear, M. R., Hohenhaus, D. M., Kelly, G., Kamal, N. A., Gupta, P. K., Labzin, L. I., Schroder, K., Garceau, V., Barbero, S., Iyer, A., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.496281 · Cited by 105
Heideman, M. R., Wilting, R. H., Yanover, E., Velds, A., de Jong, J., Kerkhoven, R. M., Jacobs, H., Wessels, L. F. A., & Dannenberg, J. (2013) · Blood · doi:10.1182/blood-2012-08-450916 · Cited by 104
Hu, Y., Lu, W., Chen, G., Zhang, H., Jia, Y., Wei, Y., Yang, H., Zhang, W., Fiskus, W. C., Bhalla, K. N., et al. (2010) · Blood · doi:10.1182/blood-2009-11-256354 · Cited by 104
Histone Deacetylase Inhibitors Equipped with Estrogen Receptor Modulation Activity
Gryder, B. E., Rood, M. K., Johnson, K. A., Patil, V., Raftery, E. D., Yao, L.-P. D., Rice, M., Azizi, B., Doyle, D. F., & Oyelere, A. K. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400467w · Cited by 102
Dudakovic, A., Evans, J. M., Li, Y., Middha, S., McGee‐Lawrence, M. E., van Wijnen, A. J., & Westendorf, J. J. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.489732 · Cited by 101
Inhibition of Histone Deacetylase 3 Causes Replication Stress in Cutaneous T Cell Lymphoma
Wells, C. E., Bhaskara, S., Stengel, K. R., Zhao, Y., Sirbu, B., Chagot, B., Cortez, D., Khabele, D., Chazin, W. J., Cooper, A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068915 · Cited by 100
Vascular histone deacetylation by pharmacological HDAC inhibition
Rafehi, H., Balcerczyk, A., Lunke, S., Kaspi, A., Ziemann, M., Kurup, H. K. N., Okabe, J., Khurana, I., Ooi, J. Y. Y., Khan, A. W., et al. (2014) · Genome Research · doi:10.1101/gr.168781.113 · Cited by 98
Discovery of the First Histone Deacetylase 6/8 Dual Inhibitors
Olson, D. E., Wagner, F. F., Kaya, T., Gale, J. P., Aidoud, N., Davoine, E. L., Lazzaro, F., Weïwer, M., Zhang, Y., & Holson, E. B. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400390r · Cited by 98
HDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cells
Song, W., Tai, Y.-T., Tian, Z., Hideshima, T., Chauhan, D., Nanjappa, P., Exley, M. A., Anderson, K. C., & Munshi, N. C. (2010) · Leukemia · doi:10.1038/leu.2010.244 · Cited by 96
Stumpel, D. J. P. M., Schneider, P., Seslija, L., Osaki, H., Williams, O., Pieters, R., & Stam, R. W. (2011) · Leukemia · doi:10.1038/leu.2011.278 · Cited by 95
Cabrero, J. R., Serrador, J. M., Barreiro, O., Mittelbrunn, M., Naranjo-Suárez, S., Martín-Cófreces, N., Vicente-Manzanares, M., Mazitschek, R., Bradner, J. E., Ávila, J., et al. (2006) · Molecular Biology of the Cell · doi:10.1091/mbc.e06-01-0008 · Cited by 95
Murakami, T., Sato, A., Chun, N. A. L., Hara, M., Naito, Y., Kobayashi, Y., Kano, Y., Ohtsuki, M., Furukawa, Y., & Kobayashi, E. (2008) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5701216 · Cited by 92
Sodium butyrate induces growth arrest and senescence-like phenotypes in gynecologic cancer cells
Terao, Y., Nishida, J.-I., Horiuchi, S., Rong, F., Ueoka, Y., Matsuda, T., Kato, H., Furugen, Y., Yoshida, K., Kato, K., et al. (2001) · International Journal of Cancer · doi:10.1002/ijc.1448 · Cited by 91
Northrop, J. K., Wells, A. D., & Shen, H. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.2.865 · Cited by 91
Lu, J., Yang, C., Chen, M., Ye, D. Y., Lonser, R. R., Brady, R. O., & Zhuang, Z. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119181109 · Cited by 90
Gray, S. G., Qian, C., Furge, K., Guo, X., & Teh, B. T. (2004) · International Journal of Oncology · doi:10.3892/ijo.24.4.773 · Cited by 90
Whitecross, K. F., Alsop, A. E., Cluse, L. A., Wiegmans, A. P., Banks, K.-M., Coomans, C. P., Peart, M. J., Newbold, A., Lindemann, R. K., & Johnstone, R. W. (2008) · Blood · doi:10.1182/blood-2008-05-156851 · Cited by 90
Self-citationFann, M., Godlove, J. M., Catalfamo, M., Wood, W. H., Chrest, F. J., Chun, N., Granger, L., Wersto, R., Madara, K., Becker, K., et al. (2006) · Blood · doi:10.1182/blood-2006-02-005520 · Cited by 86
Nguyen, T., Dai, Y., Attkisson, E., Kramer, L. B., Jordan, N., Nguyen, N., Kolluri, N., Müschen, M., & Grant, S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0234 · Cited by 84
Wang, J., Pursell, N. W., Samson, M., Atoyan, R., Ma, A. W., Selmi, A., Xu, W., Cai, X., Voi, M., Savagner, P., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1045 · Cited by 83
Chen, J.-B., Chern, T., Wei, T.-T., Chen, C., Lin, J., & Fang, J. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400179b · Cited by 81
HDAC inhibitors: modulating leukocyte differentiation, survival, proliferation and inflammation
Sweet, M. J., Shakespear, M. R., Kamal, N. A., & Fairlie, D. P. (2011) · Immunology and Cell Biology · doi:10.1038/icb.2011.88 · Cited by 81
HDAC inhibitor therapy in autoimmunity and transplantation
Hancock, W. W., Akimova, T., Beier, U. H., Liu, Y., & Wang, L. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-200593 · Cited by 80
Ruefli, A. A., Bernhard, D., Tainton, K. M., Kofler, R., Smyth, M. J., & Johnstone, R. W. (2002) · International Journal of Cancer · doi:10.1002/ijc.10327 · Cited by 78
Self-citationCantley, M. D., & Haynes, D. R. (2013) · Inflammopharmacology · doi:10.1007/s10787-012-0166-0 · Cited by 77
Spinal muscular atrophy: An update on therapeutic progress
Seo, J., Howell, M. D., Singh, N. N., & Singh, R. N. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.08.005 · Cited by 77
Faller, D. V., Mentzer, S. J., & Perrine, S. P. (2001) · Current Opinion in Oncology · doi:10.1097/00001622-200109000-00008 · Cited by 76
Xiao, J. J., Foraker, A. B., Swaan, P. W., Liu, S., Huang, Y. S., Zunyan Dai, Y., Chen, J., Sadée, W., Byrd, J. C., Marcucci, G., et al. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.072033 · Cited by 74
Incorporation of histone deacetylase inhibition into the structure of a nuclear receptor agonist
Tavera-Mendoza, L. E., Quach, T. D., Dabbas, B., Hudon, J., Liao, X., Palijan, A., Gleason, J. L., & White, J. H. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709279105 · Cited by 73
Kleinschmidt, M. A., de Graaf, P., van Teeffelen, H. A. A. M., & Timmers, H. T. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041446 · Cited by 72
Kwon, D. Y., Motley, W. W., Fischbeck, K. H., & Burnett, B. G. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr288 · Cited by 71
Drug Targeting to Monocytes and Macrophages Using Esterase-Sensitive Chemical Motifs
Needham, L. A., Davidson, A. H., Bawden, L. J., Belfield, A. J., Bone, E. A., Brotherton, D. H., Bryant, S., Charlton, M. H., Clark, V. L., Davies, S. J., et al. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.183640 · Cited by 71
Newbold, A., Lindemann, R. K., Cluse, L. A., Whitecross, K. F., Dear, A. E., & Johnstone, R. W. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2256 · Cited by 70
Self-citationBarneda‐Zahonero, B., Román-González, L., Collazo, O., Rafati, H., Islam, A. B. M. M. K., Bussmann, L. H., Tullio, A. D., de Andrés-Aguayo, L., Graf, T., López-Bigas, N., et al. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003503 · Cited by 67
Ritchie, D., Piekarz, R., Blombery, P. A., Karai, L., Pittaluga, S., Jaffe, E. S., Raffeld, M. A., Janik, J. E., Prince, H. M., & Bates, S. E. (2009) · Haematologica · doi:10.3324/haematol.2009.008607 · Cited by 67
A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth
Kaliszczak, M., Trousil, S., Åberg, O., Perumal, M., Nguyen, Q.-D., & Aboagye, E. O. (2013) · British Journal of Cancer · doi:10.1038/bjc.2012.576 · Cited by 66
Effects of a novel arginine methyltransferase inhibitor on T‐helper cell cytokine production
Bonham, K. S., Hemmers, S., Lim, Y., Hill, D. M., Finn, M. G., & Mowen, K. A. (2010) · FEBS Journal · doi:10.1111/j.1742-4658.2010.07623.x · Cited by 65
Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors
Tessier, P., Smil, D. V., Wahhab, A., Leit, S. M., Rahil, J. F., Li, Z., Déziel, R., & Besterman, J. M. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.08.010 · Cited by 65
Newbold, A., Salmon, J. M., Martin, B. P., Stanley, K., & Johnstone, R. W. (2013) · Oncogene · doi:10.1038/onc.2013.482 · Cited by 62
Self-citationThe role of histone acetylation versus DNA damage in drug-induced senescence and apoptosis
Rebbaa, A., Zheng, X. S., Chu, F., & Mirkin, B. L. (2006) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401895 · Cited by 61
Dual-acting histone deacetylase-topoisomerase I inhibitors
Guerrant, W., Patil, V., Canzoneri, J. C., Yao, L.-P. D., Hood, R., & Oyelere, A. K. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.03.108 · Cited by 61
Tranylcypromine: New perspectives on an “old” drug
Frieling, H., & Bleich, S. (2006) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-006-0660-8 · Cited by 60
HDACs and the senescent phenotype of WI-38 cells
Place, R. F., Noonan, E. J., & Giardina, C. A. (2005) · BMC Cell Biology · doi:10.1186/1471-2121-6-37 · Cited by 59
FK228 inhibits Hsp90 chaperone function in K562 cells via hyperacetylation of Hsp70
Wang, Y., Wang, S., Zhang, X., Zhao, M., Hou, C., Xu, Y.-J., Du, Z., & Yu, X. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.03.076 · Cited by 59
CBFβ is critical for AML1-ETO and TEL-AML1 activity
Roudaia, L., Cheney, M. D., Manuylova, E., Chen, W., Morrow, M., Park, S., Lee, C.-T., Kaur, P., Williams, O., Bushweller, J. H., et al. (2009) · Blood · doi:10.1182/blood-2008-03-147207 · Cited by 59
Shen, L., & Пили, Р. (2012) · OncoImmunology · doi:10.4161/onci.20306 · Cited by 58
Leiva, M., Moretti, S., Soilihi, H., Pallavicini, I., Peres, L., Mercurio, C., Dal Zuffo, R., Minucci, S., & de Thé, H. (2012) · Leukemia · doi:10.1038/leu.2012.39 · Cited by 58
Dupéré-Richer, D., Kinal, M., Ménasché, V., Nielsen, T. H., Rincon, S. V. D., Pettersson, F., & Miller, W. H. (2013) · Cell Death and Disease · doi:10.1038/cddis.2012.210 · Cited by 55
Fredly, H., Ersvær, E., Kittang, A. O., Tsykunova, G., Gjertsen, B. T., & Bruserud, Ø. (2013) · Clinical Epigenetics · doi:10.1186/1868-7083-5-13 · Cited by 55
Weber, D. M., Graef, T. T., Hussein, M. A., Sobecks, R. M., Schiller, G. J., Lupinacci, L. C., Hardwick, J. S., & Jagannath, S. (2012) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2012.07.007 · Cited by 51
Molecular and Biologic Analysis of Histone Deacetylase Inhibitors with Diverse Specificities
Newbold, A., Matthews, G. M., Bots, M. L., Cluse, L. A., Clarke, C. J. P., Banks, K.-M., Cullinane, C. M., Bolden, J. E., Christiansen, A. J., Dickins, R. A., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0626 · Cited by 50
Self-citationDevelopment of a Chimeric c-Src Kinase and HDAC Inhibitor
Ko, K. S., Steffey, M. E., Brandvold, K. R., & Soellner, M. B. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400175d · Cited by 50
Class IIA HDACs in the regulation of neurodegeneration
Majdzadeh, N., Morrison, B. E., & D’Mello, S. R. (2007) · Frontiers in bioscience · doi:10.2741/2745 · Cited by 49
Towards Isozyme-Selective HDAC Inhibitors For Interrogating Disease
Gupta, P., C. Reid, R., Iyer, A., J. Sweet, M., & P. Fairlie, D. (2012) · Current Topics in Medicinal Chemistry · doi:10.2174/156802612802652420 · Cited by 47
Ossenkoppele, G. J., Lowenberg, B., Zachee, P., Vey, N., Breems, D., Van de Loosdrecht, A. A., Davidson, A. H., Wells, G., Needham, L., Bawden, L., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12359 · Cited by 47
Trichostatin A, an inhibitor of histone deacetylase, inhibits hypoxia-induced angiogenesis
Williams, R. J. (2001) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.10.8.1571 · Cited by 46
Hsieh, I.-N., Liou, J.-P., LEE, H. Y., Lai, M.-J., Li, Y.-H., & Yang, C.-R. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.133 · Cited by 45
New, M., Olzscha, H., Liu, G., Khan, O., Stimson, L., McGouran, J. F., Kerr, D. J., Coutts, A. S., Kessler, B. M., Middleton, M. R., et al. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.47 · Cited by 45
Soragni, E., Xu, C., Plasterer, H. L., Jacques, V., Rusche, J. R., & Gottesfeld, J. M. (2012) · Journal of Child Neurology · doi:10.1177/0883073812448533 · Cited by 44
STAT1 Signaling Is Not Regulated by a Phosphorylation-Acetylation Switch
Antunes, F., Marg, A., & Vinkemeier, U. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.05300-11 · Cited by 44
Saha, A., Pandian, G. N., Sato, S., Taniguchi, J., Hashiya, K., Bando, T., & Sugiyama, H. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.05.002 · Cited by 39
Harahap, I. S. K., Saito, T., San, L. P., Sasaki, N., Gunadi, G., Nurputra, D. K., Yusoff, S., Yamamoto, T., Morikawa, S., Nishimura, N., et al. (2011) · Brain and Development · doi:10.1016/j.braindev.2011.04.010 · Cited by 38
Multi-Targeted Histone Deacetylase Inhibitors in Cancer Therapy
Ai, T., Cui, H., & Chen, L. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712798918842 · Cited by 38
Vitamin D receptor agonist/histone deacetylase inhibitor molecular hybrids
Lamblin, M., Dabbas, B., Spingarn, R., Mendoza‐Sanchez, R., Wang, T. T., An, B., Huang, D. C., Kremer, R. B., White, J. H., & Gleason, J. L. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.03.078 · Cited by 37
HDAC Inhibitor Modulation of Proteotoxicity as a Therapeutic Approach in Cancer
McConkey, D. J., White, M. C., & Yan, W. (2012) · Advances in cancer research · doi:10.1016/b978-0-12-394387-3.00004-5 · Cited by 35
Zhou, G., Du, T., & Roizman, B. (2013) · Viruses · doi:10.3390/v5051208 · Cited by 32
A Chimeric SERM–Histone Deacetylase Inhibitor Approach to Breast Cancer Therapy
Patel, H., Siklos, M. I., Abdelkarim, H., Mendonca, E. L., Vaidya, A. S., Petukhov, P. A., & Thatcher, G. R. J. (2013) · ChemMedChem · doi:10.1002/cmdc.201300270 · Cited by 27
Differential regulation of the SMN2 gene by individual HDAC proteins
Evans, M. C., Cherry, J. J., & Androphy, E. J. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.09.011 · Cited by 24
Gabrielli, B. G., & Maybury, M. K. (2012) · Advances in cancer research · doi:10.1016/b978-0-12-394387-3.00001-x · Cited by 23
The acute promyelocytic leukaemia success story: curing leukaemia through targeted therapies
Rice, K. L., & de Thé, H. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12208 · Cited by 23
Schmudde, M., Friebe, E., Sonnemann, J., Beck, J. F., & Bröker, B. M. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.02.024 · Cited by 22
Chen, G., Wang, L., Wang, J., Chen, K., Zhao, M., Sun, Z., Wang, S., Zheng, H., Yang, J., & Wu, C. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.04.067 · Cited by 20
Yu, W., Wang, J., Jin, J., Qian, W., Qian, J., Cheng, Y., & Wang, L. (2011) · Leukemia Research · doi:10.1016/j.leukres.2011.05.014 · Cited by 19
Epigenetic regulation of CD8+ T-lymphocyte mediated suppression of HIV-1 replication
Saunders, K. O., Freel, S. A., Overman, R. G., Cunningham, C. K., & Tomaras, G. D. (2010) · Virology · doi:10.1016/j.virol.2010.06.001 · Cited by 18
Martin, B. P., Frew, A. J., Bots, M. L., Fox, S. B., Long, F., Takeda, K., Yagita∥, H., Atadja, P. W., Smyth, M. J., & Johnstone, R. W. (2010) · International Journal of Cancer · doi:10.1002/ijc.25594 · Cited by 14
Self-citationKong, H., Tian, S., Kong, Y., Du, G., Zhang, L., Jung, M., Dritschilo, A., & Brown, M. L. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0832-3 · Cited by 10
SP0190 Improving rheumatologic care and education in the republic of macedonia
Ognenovski, V. M. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-eular.1665 · Cited by 1
Cited by
Acetyl coenzyme A: a central metabolite and second messenger
Pietrocola, F., Galluzzi, L., Bravo-San Pedro, J. M., Madeo, F., & Kroemer, G. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.05.014 · Cited by 1,378
HDACs and HDAC Inhibitors in Cancer Development and Therapy
Li, Y., & Seto, E. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026831 · Cited by 1,284
Functions and mechanisms of non-histone protein acetylation
Narita, T., Weinert, B. T., & Choudhary, C. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0081-3 · Cited by 1,232
Histone Deacetylase Inhibitors as Anticancer Drugs
Eckschlager, T., Plch, J., Stiborova, M., & Hrabeta, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071414 · Cited by 1,206
Targeting the cancer epigenome for therapy
Jones, P. A., Issa, J.-P. J., & Baylin, S. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.93 · Cited by 1,128
Metadata
- Authors
- Falkenberg, K. J., & Johnstone, R. W.
- Affiliations
- Peter MacCallum Cancer Centre (AU)
- The University of Melbourne (AU)
- Corresponding author
- Johnstone, Ricky W.
- ORCID
- Johnstone, Ricky W.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-08-18
- Volume
- 13
- Issue
- 9
- Pages
- 673-691
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2046345187
- Cited by
- 1,564
- References
- 281
- Citations by year
- 2026: 82 · 2025: 110 · 2024: 89 · 2023: 96 · 2022: 121 · 2021: 133 · 2020: 160 · 2019: 146 · 2018: 134 · 2017: 166 · 2016: 208 · 2015: 108 · 2014: 8
- FWCI
- 15.82
- Type
- journal article
- Language
- en
- Update notices
- addendum (2015-02-27)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- histone deacetylase, histone deacetylase inhibitors, epigenetic regulation, cancer, neurological disorders, immune disorders, small molecule inhibitors, lysine deacetylation, epigenetic aberrations, drug development
- MeSH terms
- Animals, Histone Deacetylases, Humans, Immune System Diseases, Neoplasms, Nervous System Diseases, Epigenesis, Genetic, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.